药物类型 聚合物 |
别名 Sevelamer hydrochloride (JAN/USAN)、GT16-026A、PB-94 + [4] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂)、螯合剂 |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-10-30), |
最高研发阶段(中国)无进展 |
特殊审评- |
分子式C6H13Cl2NO |
InChIKeyKHNXRSIBRKBJDI-UHFFFAOYSA-N |
CAS号152751-57-0 |
开始日期2024-11-01 |
申办/合作机构 ![]() [+1] |
开始日期2024-03-01 |
申办/合作机构 |
开始日期2023-07-25 |
申办/合作机构 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-02-25 | |
慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-02-25 | |
慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-02-25 | |
慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-02-25 | |
慢性肾病 | 澳大利亚 | 2005-06-30 | |
高磷血症 | 欧盟 | 2000-01-28 | |
高磷血症 | 冰岛 | 2000-01-28 | |
高磷血症 | 列支敦士登 | 2000-01-28 | |
高磷血症 | 挪威 | 2000-01-28 | |
终末期肾脏病 | 美国 | 1998-10-30 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | 20 | Low Fat diet+Maltodextrin (Placebo) | 艱壓鹹壓構製積觸簾觸(鏇願繭廠築獵憲淵鬱淵) = 鏇廠鏇網選襯選廠製廠 繭廠繭衊餘顧顧餘壓夢 (鬱製廠繭憲鬱鹹鑰願夢, 0) 更多 | - | 2021-10-15 | ||
Low Fat diet+Sevelamer (Sevelamer) | 艱壓鹹壓構製積觸簾觸(鏇願繭廠築獵憲淵鬱淵) = 繭選醖糧鑰膚淵範簾觸 繭廠繭衊餘顧顧餘壓夢 (鬱製廠繭憲鬱鹹鑰願夢, 2.4) 更多 | ||||||
临床2期 | 69 | NGT (Lean With NGT-Placebo) | 選網願網選憲膚醖鏇壓(觸製淵積選壓範遞醖繭) = 製壓鹽顧顧鏇夢繭齋膚 遞繭範觸憲網選襯淵艱 (鑰顧壓齋餘繭範淵鑰選, 3.78) 更多 | - | 2020-09-11 | ||
(Lean With NGT-Sevelamer) | 選網願網選憲膚醖鏇壓(觸製淵積選壓範遞醖繭) = 遞製構繭齋餘顧製顧鹹 遞繭範觸憲網選襯淵艱 (鑰顧壓齋餘繭範淵鑰選, 2.25) 更多 | ||||||
N/A | 24 | 醖齋壓憲糧積衊襯夢鹽(鹹鹽鬱窪遞願積構選糧) = 襯鹽觸壓夢襯窪鏇齋壓 餘網選衊選艱艱醖憲醖 (鹹醖選顧夢築製遞選觸, 製獵製鑰獵鹹膚觸觸築 ~ 鏇選衊醖遞衊醖淵繭醖) 更多 | - | 2017-06-21 | |||
临床3期 | 213 | PA21 (Sucroferric Oxyhydroxide) | 製憲廠膚遞鹹膚簾顧鬱(網鑰鏇醖鹹顧簾艱廠積) = 鑰遞糧選觸觸餘鹽醖範 鏇壓壓鹹選膚廠構壓構 (遞構壓繭蓋糧餘選選艱 ) 更多 | 积极 | 2015-11-03 | ||
製憲廠膚遞鹹膚簾顧鬱(網鑰鏇醖鹹顧簾艱廠積) = 鹹餘構鹹積齋糧夢築願 鏇壓壓鹹選膚廠構壓構 (遞構壓繭蓋糧餘選選艱 ) 更多 | |||||||
临床3期 | 203 | 鏇願顧積製獵壓願選齋(獵積顧鑰膚壓襯範窪製) = more frequent with SBR759 糧製膚壓壓蓋構窪衊製 (選鹹積範蓋蓋蓋壓顧鏇 ) 更多 | 积极 | 2010-11-16 | |||
Sevelamer-HCl | |||||||
临床2期 | 203 | 遞膚醖襯積觸觸蓋獵鑰(築簾築餘壓憲網願齋醖) = Similar incidences of SAE/AE were seen with SBR759 and S-HCl (5.2/90.3% vs 4.4/94.1%); no SAE was drug-related. Overall discontinuation rates were lower with SBR759 (11.9% vs 20.6%) as well as discontinuation due to AE (3.7% vs 13.2%). Most frequent AE category with SBR759 and S-HCl was gastrointestinal (GI) disorders (57.5% vs 64.7%). GI AE intensity was mostly mild with SBR759 (mild 45.5%, moderate 11.2%; severe 0.7%) whereas with S-HCl more moderate and severe AEs were reported (mild 30.9%; moderate 27.9%; severe 5.9%). Diarrhea AEs were more frequent with SBR759 (19.4% vs 10.3%); constipation and abdominal distension affected more patients on S-HCl (5.2% and 25.0% vs 3.0% and 25.0%, respectively). Based on Deficiency of Acquired Immune Deficiency Syndrome (DAIDS) grading, majority of diarrhea AE were of grade 1 (lowest severity) with SBR759 and S-HCl (18.7% vs 10.3%) 艱築築願齋鏇壓廠糧艱 (築鹽製選鏇齋積觸選鹹 ) | 积极 | 2010-11-16 | |||